Request Demo
Last update 27 Feb 2026
Gemnelatinib
Last update 27 Feb 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms GST HG 161, GST HG-161, GST-HG161 |
Target |
Action inhibitors |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC30H29FN6O2 |
InChIKeyUDDRTVZAZBIBBN-HXUWFJFHSA-N |
CAS Registry2225123-30-6 |
Related
3
Clinical Trials associated with GemnelatinibCTR20190632
一项开放、单次及多次给药、剂量递增和扩展的I期临床试验
[Translation] An open-label, single- and multiple-dose, dose-escalation and expansion Phase I clinical trial
NCT04228406
Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of the Selective c-MET Inhibitor GST-HG161 in Patients With Advanced or Metastatic Solid Tumors
ChiCTR1900024324
Safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy evaluation of the selective c-MET inhibitor GST-HG161 in patients with advanced or metastatic solid tumors: An open, single and multiple administration, dose escalation, and expanded phase I trial
100 Clinical Results associated with Gemnelatinib
Login to view more data
100 Translational Medicine associated with Gemnelatinib
Login to view more data
100 Patents (Medical) associated with Gemnelatinib
Login to view more data
100 Deals associated with Gemnelatinib
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| c-met mutant solid tumour | Phase 1 | China | 01 Jul 2019 | |
| Hepatocellular Carcinoma | Phase 1 | China | 01 Jul 2019 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 28 Jun 2019 | |
| Metastatic Solid Tumor | Phase 1 | China | 28 Jun 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | - | dhmaziuqar(hrswddbtza) = rlybwsimix hkrmoyfajl (ckxdfntydp ) View more | Positive | 29 May 2020 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free